



Discover Generics

Cost-Effective CT & MRI Contrast Agents



[VIEW CATALOG](#)

AJNR

This information is current as of September 12, 2025.

RNA-Sequencing Analysis of Messenger RNA/MicroRNA in a Rabbit Aneurysm Model Identifies Pathways and Genes of Interest

M. Holcomb, Y.-H. Ding, D. Dai, R.J. McDonald, J.S. McDonald, D.F. Kallmes and R. Kadirvel

AJNR Am J Neuroradiol 2015, 36 (9) 1710-1715

doi: <https://doi.org/10.3174/ajnr.A4390>

<http://www.ajnr.org/content/36/9/1710>

RNA-Sequencing Analysis of Messenger RNA/MicroRNA in a Rabbit Aneurysm Model Identifies Pathways and Genes of Interest

M. Holcomb, Y.-H. Ding, D. Dai, R.J. McDonald, J.S. McDonald, D.F. Kallmes, and R. Kadirvel



ABSTRACT

BACKGROUND AND PURPOSE: Rabbit aneurysm models are used for the testing of embolization devices and elucidating the mechanisms of human intracranial aneurysm growth and healing. We used RNA-sequencing technology to identify genes relevant to induced rabbit aneurysm biology and to identify genes and pathways of potential clinical interest. This process included sequencing microRNAs, which are important regulatory noncoding RNAs.

MATERIALS AND METHODS: Elastase-induced saccular aneurysms were created at the origin of the right common carotid artery in 6 rabbits. Messenger RNA and microRNA were isolated from the aneurysm and from the control left common carotid artery at 12 weeks and processed by using RNA-sequencing technology. The results from RNA sequencing were analyzed by using the Ingenuity Pathway Analysis tool.

RESULTS: A total of 9396 genes were analyzed by using RNA sequencing, 648 (6.9%) of which were found to be significantly differentially expressed between the aneurysms and control tissues ($P < .05$; false-discovery rate, < 0.01 ; fold change, > 2 or $< .5$). Of these genes, 614 were mapped successfully, 143 were down-regulated, and 471 were up-regulated in the aneurysms as compared with controls. Using the same criteria for significance, 3 microRNAs were identified as down-regulated and 5 were identified as up-regulated. Pathway analysis associated these genes with inflammatory response, cellular migration, and coagulation, among other functions and pathologies.

CONCLUSIONS: RNA-sequencing analysis of rabbit aneurysms revealed differential regulation of some key pathways, including inflammation and antigen presentation. *ANKRD1* and *TACRI* were identified as genes of interest in the regulation of matrix metalloproteinases.

ABBREVIATIONS: IPA = Ingenuity Pathway Analysis; miRNA = microRNA

Cerebral aneurysm biology is poorly understood in general, with the mechanisms for formation, growth, healing, and rupture all in need of further elucidation. Understanding the underlying biology of aneurysms involves detailing the expression patterns of large clusters of genes and the microRNAs (miRNAs) that regulate them, alongside other biologic considerations such as hemodynamics, which involves computational modeling of the fluid dynamics of the aneurysm and surrounding vessels and has been examined in a number of recent studies.¹⁻⁵ miRNAs are small noncoding RNAs (~20

bp) that bind messenger RNA and mediate its degradation or repression (Fig 1). Therefore, miRNA is an important regulatory molecule, and it is known to play a role in a variety of pathologies.⁶⁻¹² There are only a handful of previous studies that have profiled miRNA expression in either human intracranial aneurysms or relevant animal models¹³⁻¹⁵ and a small number of studies that have focused on the roles of particular miRNAs.^{16,17} Already these studies are revealing potential biomarkers¹³ and the importance of these regulatory molecules.

Rabbit elastase-induced experimental aneurysms have been used to study aneurysm occlusion devices and underlying aneurysm biology.^{2,18-22} These previous studies relied on detailed information about the biologic environment of experimental rabbit aneurysms. Existing studies have used RNA microarray data to quantify gene expression.^{18,23-25} Compared with microarrays, next-generation RNA sequencing offers increased specificity and sensitivity, broader dynamic range, and the ability to detect new transcripts and isoforms.²⁶ It also enables the detection of miRNA. In this study, we used RNA sequencing to establish dif-

Received August 21, 2014; accepted after revision January 30, 2015.

From the Neuroradiology Research Laboratory, Mayo Clinic, Rochester, Minnesota. This work was supported by research grant NS076491 from the National Institutes of Health.

Please address correspondence to Ramanathan Kadirvel, PhD, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: kadir@mayo.edu

Indicates open access to non-subscribers at www.ajnr.org

Indicates article with supplemental on-line table.

<http://dx.doi.org/10.3174/ajnr.A4390>




FIG 1. Diagram of miRNA regulation of gene expression. mRNA indicates messenger RNA; ORF, open reading frame; Pol, polymerase; Pri-miRNA, primary microRNA; RISC, RNA-induced silencing complex.

ferential expression patterns of messenger RNA and miRNA in experimental rabbit aneurysms.

MATERIALS AND METHODS

Aneurysm Creation and Tissue Harvest

The Institutional Animal Care and Use Committee approved all procedures before initiation of the study. An elastase-induced sacular aneurysm was created in each of 6 New Zealand white rabbits by using the rabbit elastase model.²⁷ Aneurysm and contralateral common carotid artery samples were harvested 12 weeks after aneurysm creation. These tissue samples were then immediately frozen in liquid nitrogen and stored at -70°C until they were ready for messenger RNA/miRNA extraction.

Messenger RNA and miRNA Extraction

RNA was isolated from the frozen tissues by using an miRNeasy mini kit (Qiagen, Valencia, California). The quantity of RNA was measured by using spectrophotometry, and the integrity of the RNA was confirmed by electrophoretic separation using the 2100 Bioanalyzer (Agilent Technologies, Palo Alto, California). The quality of the samples was determined by RNA integrity number.²⁸ An RNA integrity number of >6 is considered acceptable for sequencing. One aneurysm sample that did not meet the required RNA integrity number was excluded, along with its paired control from the study, so that paired analysis could be performed on the other samples. The remaining samples ($n = 5$ each for the controls and the aneurysms) were used for RNA-sequencing analysis.

RNA Sequencing

RNA libraries were prepared according to the manufacturer's instructions for the TruSeq RNA sample prep kit version 2 (Illumina, San Diego, California). Then, the libraries were loaded onto paired-end flow cells following Illumina's standard protocol by using the Illumina cBot and cBot paired-end cluster kit (version 3). The flow cells were sequenced on an Illumina HiSeq 2000 using a TruSeq SBS sequencing kit (version 3) and HCS (version 2.0.12) data-collection software. Base calling was performed by using Illumina's RTA (version 1.17.21.3).

NEBNext miRNA Sequencing

miRNA libraries were prepared according to the manufacturer's instructions for the NEBNext Multiplex small-RNA kit (New England Biolabs, Ipswich, Massachusetts). Then, the libraries were loaded onto paired-end flow cells following Illumina's standard protocol by using the Illumina cBot and cBot paired-end cluster kit (version 3). The flow cells were sequenced on an Illumina HiSeq 2000 using a TruSeq SBS sequencing kit (version 3) and HCS (version 2.0.12) data-collection software. Base calling was performed by using Illumina's RTA (version 1.17.21.3).

Bioinformatics Analysis

Processing of the messenger RNA data was performed by using MAP-RSeq (version 1.2.1.3).²⁹ MAP-RSeq consists of the following steps: alignment, quality control, obtaining genomic features for each sample, and summarizing the data across samples. The pipeline provides detailed quality-control data to estimate the distance between paired-end reads, evaluates the sequencing depth for alternate splicing analysis, determines the rate of duplicate reads, and calculates the read depth across genes by using RSeQC software (version 2.3.2).³⁰ Paired-end reads were aligned by TopHat (version 2.0.6)³¹ against the April 2009 oryCun2 genome build by using the bowtie1³² aligner option. Gene counts were generated by using HTSeq software (version 0.5.3p9),³³ and the gene-annotation files were obtained from Ensembl (ftp://ftp.ensembl.org/pub/release-75/gtf/oryctolagus_cuniculus/Oryctolagus_cuniculus.OryCun2.0.75.gtf.gz) and the University of California Santa Cruz (<http://hgdownload.soe.ucsc.edu/downloads.html#rabbit>). Differential expression in a sample's aneurysm tissue compared with that in the same sample's normal tissue was computed by using the edgeR algorithm (version 2.6.2)³⁴ across all samples. EdgeR (or empirical analysis of digital gene expression in R, an open-source programming environment) is a Bioconductor software package for examining differential expression of replicated count data; it calculates the log fold change, the P value, and the false-discovery rate between the control and experimental conditions. Human orthologs were assigned by using

ExoLocator.³⁵ The pathway analysis leveraged the Ingenuity Pathway Analysis (IPA)³⁶ software to identify pathways enriched with human ortholog targets.

Quantitative Real-Time Polymerase Chain Reaction

Analysis

First-strand complementary DNAs were synthesized from 500 ng of total RNA by using Superscript III first-strand synthesis (Invitrogen, Carlsbad, California). Real-time polymerase chain reaction assays were performed for osteopontin, von Willebrand factor, *TIMP1*, tyrosinase, and *TACR1* with an iCycler (Bio-Rad, Hercules, California).

Statistical Analysis

The *t*-test statistics and corresponding *P* values were used as a measure of the mean change in expression between the aneurysm and control groups relative to the variability. The *t*-test-based *P* values were adjusted for multiple comparisons by using the false-discovery-rate multiple-correction approach.³⁷

Table 1: miRNA expression data

Mature miRNA	Fold Change	<i>P</i> Value	FDR
hsa-miR-1	0.48	4.62E-05	1.01E-03
hsa-miR-9-5p	0.43	4.80E-05	1.01E-03
hsa-miR-10a-5p	2.66	8.83E-09	4.66E-07
hsa-miR-10b-5p ^a	2.45	3.47E-07	1.47E-05
hsa-miR-21-5p	3.51	4.43E-11	4.67E-09
hsa-miR-34a-5p	2.34	1.15E-04	2.02E-03
hsa-miR-34c-5p ^b	3.79	1.28E-06	4.38E-05
hsa-miR-146a-5p	3.68	1.45E-06	4.38E-05
hsa-miR-146b-5p ^c	3.32	9.08E-11	6.39E-09
hsa-miR-204-5p	0.48	7.32E-06	1.93E-04
hsa-miR-223-3p	3.95	6.79E-12	1.43E-09

Note:—FDR indicates false discovery rate.

^a Grouped with miR-10a-5p by IPA for targeting purposes.

^b Grouped with miR-34a-5p by IPA for targeting purposes.

^c Grouped with miR-146a-5p by IPA for targeting purposes.

Compared with controls, genes in aneurysms with a significant difference, determined by a *P* value of < .05, a false discovery rate of <0.01, and a fold change of >2, were considered up-regulated, whereas those with a *P* value of <.05, a false discovery rate of <0.01, and a fold change of <.5 were considered down-regulated.

RESULTS

Using the criteria discussed above for differential expression, 648 of 9396 (6.9%) genes were identified as being differentially expressed. Of these genes, 614 were mapped successfully; 143 were down-regulated, and 471 were up-regulated (On-line Table). The 34 unmapped genes consisted of rabbit genes for which no ortholog could be determined. Of 211 miRNAs measured, 11 (5.2%) mature miRNAs were identified as being differentially expressed by using the same criteria as were used for messenger RNA. Targeting information was available for 8 of them that target 230 genes that have been differentially expressed. Increased expression was seen in 5 of the miRNAs, and decreased expression was seen in 3 (Table 1).

Pathways

The most up-regulated pathways are shown in Table 2 and Fig 2. The first 4 pathways, all related to immune response, have the leukocyte antigen genes (*HLA*) in common. Another pathway of interest in aneurysms is coagulation. When comparing aneurysm tissue with control tissue, IPA identified 50 up-regulated and 12 down-regulated genes related to coagulation, which includes 9 types of collagen, with 8 being up-regulated and 1 (type 28 α 1) being down-regulated (0.29-fold).

Biologic Functions of Interest

Inflammatory Response. The inflammatory response is projected to be a pathway of major up-regulation (*z* score, 4.387; *P* =

Table 2: Most up-regulated canonical pathways, determined by IPA

Canonical Biologic Pathway	No. of Genes Up-Regulated	Genes	No. of Genes Down-Regulated	Gene(s)
Dendritic cell maturation	25	<i>CD80</i> , <i>CD83</i> , <i>CD86</i> , <i>CD1C</i> , <i>COL10A1</i> , <i>COL1A1</i> , <i>COL1A2</i> , <i>FCGR1B</i> , <i>FCGR2A</i> , <i>HLA-A</i> , <i>HLA-DMA</i> , <i>HLA-DMB</i> , <i>HLA-DOB</i> , <i>HLA-DQA1</i> , <i>HLA-DRA</i> , <i>HLA-DRB1</i> , <i>HLA-DRB5</i> , <i>IL15</i> , <i>IL1B</i> , <i>IL1RL2</i> , <i>IL1RN</i> , <i>PIK3CG</i> , <i>PIK3R5</i> , <i>PLCB2</i> , <i>TREM2</i>	3	<i>CREB5</i> , <i>PLCB4</i> , <i>PLCL1</i>
Role of NFAT in regulation of the immune response	22	<i>BLNK</i> , <i>BTK</i> , <i>CD80</i> , <i>CD86</i> , <i>FCERIA</i> , <i>FCGR1B</i> , <i>FCGR2A</i> , <i>FOS</i> , <i>GNG2</i> , <i>HLA-DMA</i> , <i>HLA-DMB</i> , <i>HLA-DOB</i> , <i>HLA-DQA1</i> , <i>HLA-DRA</i> , <i>HLA-DRB1</i> , <i>HLA-DRB5</i> , <i>LCP2</i> , <i>LYN</i> , <i>PIK3CG</i> , <i>PIK3R5</i> , <i>PLCB2</i> , <i>SYK</i>	2	<i>PLCB4</i> , <i>GNAO1</i>
Antigen-presentation pathway	12	<i>CD74</i> , <i>HLA-A</i> , <i>HLA-DMA</i> , <i>HLA-DMB</i> , <i>HLA-DOB</i> , <i>HLA-DPA1</i> , <i>HLA-DPB1</i> , <i>HLA-DQA1</i> , <i>HLA-DQB2</i> , <i>HLA-DRA</i> , <i>HLA-DRB1</i> , <i>HLA-DRB5</i>	0	NA
Altered T-cell and B-cell signaling in rheumatoid arthritis	17	<i>CCL21</i> , <i>CD80</i> , <i>CD86</i> , <i>HLA-DMA</i> , <i>HLA-DMB</i> , <i>HLA-DOB</i> , <i>HLA-DQA1</i> , <i>HLA-DRA</i> , <i>HLA-DRB1</i> , <i>HLA-DRB5</i> , <i>IL15</i> , <i>IL1B</i> , <i>IL1RN</i> , <i>SPPI</i> , <i>TLR1</i> , <i>TLR8</i> , <i>TNFSF13B</i>	0	NA
Atherosclerosis signaling	19	<i>ALOX5</i> , <i>CCL2</i> , <i>CCR2</i> , <i>COL10A1</i> , <i>COL1A1</i> , <i>COL1A2</i> , <i>CXCR4</i> , <i>IL8</i> , <i>IL1B</i> , <i>IL1RN</i> , <i>LYZ</i> , <i>MSRI</i> , <i>PDGFB</i> , <i>PDGFC</i> , <i>PDGFD</i> , <i>PLA2G7</i> , <i>PLA2R1</i> , <i>SELE</i> , <i>VCAM1</i>	1	<i>RBP4</i>

Note:—NA indicates not applicable; NFAT, nuclear factor of activated T cells.




FIG 2. Top 10 canonical pathways identified by IPA. NFAT indicates nuclear factor of activated T cells.




FIG 3. Validation of RNA-sequencing results by real-time polymerase chain reaction assays. The real-time polymerase chain reactions are indicated by blue bars, and RNA sequencing is indicated by red bars. LCA indicates left carotid artery; OPN, osteopontin; TIMP1, TIMP metalloproteinase inhibitor 1; TYR, tyrosinase; TACR1, tachykinin receptor 1; vWF, von Willebrand factor.

1×10^{-31}). IPA identified 65 genes with expression directions consistent with increased activity of this pathway and 21 genes with inconsistent expression directions. CC chemokine-related molecules (ligands 2 [5.3-fold], 13 [8.7-fold], 14 [2.4-fold], 19 [7.0 fold], and 21 [8.2-fold], and receptors type 1 [32.1-fold], 2 [13.1-fold], and 5 [24.1-fold]) were up-regulated in aneurysms compared with the control arteries. The expression of interleukins was increased over the controls (ie, 7 [3.6-fold], 8 [12.4-fold], 15 [3.9-fold], and 1β [23.1-fold]), with interleukin 1 receptor type 1 also being up-regulated (2.1-fold). Caspase 1, involved in cleaving interleukin 1β into its active form, also demonstrated increased expression (11.6-fold). It is worth noting that the inter-

leukin 1 receptor antagonist, an inhibitor of the interleukin 1 receptor, was also up-regulated in the aneurysms compared with the control (25.0-fold).

Cellular Migration. Cellular migration is up-regulated (z score, 4.587; $P = 8 \times 10^{-43}$). One hundred eighteen genes with regulation directions consistent with increased migration were identified, and 61 genes with inconsistent expression directions were identified. Those involved with endothelial cell migration, which were highly expressed in aneurysms over that of the controls, included osteopontin, neuregulin 1, and fibroblast growth factor 1. Oxidized low-attenuation lipoprotein receptor 1, thrombospondin 1, and selectin E showed expression directions inconsistent with increased cellular migration in the aneurysms compared with the controls.

Validation of Microarray Data. Verification of differential gene expression in the aneurysm and control arteries was performed for 5 selected genes. Microarray gene-expression levels were comparable with those obtained by real-time polymerase chain reactions (Fig 3).

DISCUSSION

In our study we found differential expression in a large assortment of genes in tissue from experimental aneurysms compared with

the contralateral common carotid arteries. The differentially expressed genes included groups related to the inflammatory response, cellular migration, and coagulation, which may provide insight into the biologic environment of unruptured human intracranial saccular aneurysms.

The pathways up-regulated in aneurysms are involved primarily in the immune response. The top 4 pathways all center around the major histocompatibility complex, which is in agreement with literature on human intracranial aneurysms.^{38,39}

Increased expression related to inflammation was noted in human intracranial aneurysms in a number of studies.^{38–43} In particular, the up-regulation of genes related to the major histocompatibility complex,^{38,39} the complement system,^{41–43} interleukins,⁴² and chemokines^{38,42,43} has been observed. These same inflammation markers were found in our study to be up-regulated, indicating that the rabbit saccular aneurysm model maintains fidelity to the human aneurysm with respect to inflammation.

These inflammatory molecules may be up-regulated in response to a decrease in regulatory miRNA. miR-1 and miR-204–5p were both down-regulated in the tissue. miR-1 is predicted to target *CCL2* and *CXCL6* and has been observed to target *CXCR4*,⁴⁴ among others. miR-204–5p is predicted to target *CCR2*, *CCR5*, *CXCR4*, and *IL1B*, among others. miR-1 was reported to be down-regulated in human intracranial aneurysms and associated with an increased inflammatory response,¹⁴ which is in contrast to experimentally induced rat cerebral aneurysm models, which have shown increased levels of miR-1.¹⁵

Previous studies reported down-regulation of inflammatory response genes at 2 weeks in the rabbit model.²⁴ The wider array of genes accessible via RNA sequencing in our study revealed a large number of genes with expressions consistent with increased activity of this pathway. Our results are consistent with the previous results with respect to calcium-binding glycoprotein osteonectin, which was found to be up-regulated in both studies. Although we observed a lack of histologic evidence for inflammation in the rabbit aneurysm model,⁴⁵ the differential expression of inflammation-related pathways noted in this study is in accordance with that in other human studies.^{38–43}

Krischek et al³⁸ noted differentially regulated networks that had functions including cellular movement. In the first network they mentioned related to cellular movement, 9 of their 19 overexpressed genes were found to be overexpressed in our study as well, with none of the remaining 10 demonstrating underexpression.

ANKRD1 was the most up-regulated gene in our dataset, which may indicate that aneurysms heal via a wound-healing pathway. A dramatic increase in the expression of this gene is associated with tissue damage, and it plays an important role in the following wound-healing process.^{46,47} One of its modes of action is to regulate matrix metalloproteinases 13 and 10, which are involved in extracellular matrix remodeling.⁴⁸ *ANKRD1* has yet to receive attention in the context of aneurysm growth and healing, but its connection with matrix metalloproteinases and the wound-healing pathway, and that it was strongly up-regulated in our model, suggest that it should be a gene of interest.

TACR1 is the most down-regulated gene in our dataset, and it also relates to matrix metalloproteinase regulation. It is associated with increased expression of matrix metalloproteinase 2,⁴⁹ which our

group previously reported as being differentially expressed early after aneurysm formation.⁴⁵ The fact that the most up-regulated and most down-regulated genes are involved in matrix metalloproteinase regulation is reflective of the fact that the role of matrix metalloproteinases in aneurysm growth, healing, and rupture is complex, being involved both for the weakening of the aneurysm wall and also the migration of endothelial cells to the neck of the aneurysm.

Our study was limited. A rabbit RNA database was used for messenger RNA expression, whereas human databases were used for miRNA because a rabbit miRNA database is not available. The RNA collected was not from a single cell type, and bias may have been introduced by the presence of cells in the aneurysm different than those in the left common carotid artery. We used IPA for pathway analysis; different software can yield different results regarding the determination of a pathway as having been up- or down-regulated. Also, “canonical” is essentially a meaningless designation, though it is the term used in the IPA software.

CONCLUSIONS

Rabbit saccular aneurysms show differential expression in a number of pathways previously reported to play roles in aneurysm biology. This expression is dominated by antigen presentation and the inflammatory response. *TACR1* and *ANKRD1* are genes with regulatory functions over matrix metalloproteinase activity, and their roles in aneurysm biology require further elucidation.

ACKNOWLEDGMENTS

We thank Fariborz Rakhshan Rohakhtar, Debra A. Schultz, and Christopher Kolbert (Gene Expression Core) and Jared Evans, Daniel O'Brien, and Jamie Davila (Division of Biomedical Statistics and Informatics, Mayo Clinic).

Disclosures: Jennifer S. McDonald—UNRELATED: Grants/Grants Pending: GE Healthcare.* Comments: Investigator-initiated research grant for contrast-induced nephropathy. David F. Kallmes—UNRELATED: Board Membership: GE Healthcare, Comments: Cost-effectiveness board; Consultancy: ev3.* Comments: Preclinical and clinical trials; Grants/Grants Pending: MicroVention, ev3, Codman, Sequent, SurModics, and NeuroSigma, Comments: Preclinical research and clinical trials; Royalties: UVA Patent Foundation, Comments: Spine fusion. Ramanathan Kadirvel—RELATED: Grant: NIH (R01 NS076491). * Money paid to the institution.

REFERENCES

1. Chung B, Mut F, Kadirvel R, et al. **Hemodynamic analysis of fast and slow aneurysm occlusions by flow diversion in rabbits.** *J Neurointerv Surg* 2014 Oct 20 [Epub ahead of print] CrossRef Medline
2. Cebral JR, Raschi M, Mut F, et al. **Analysis of flow changes in side branches jailed by flow diverters in rabbit models.** *Int J Numer Method Biomed Eng* 2014;30:988–99 CrossRef Medline
3. Strother CM, Jiang J. **Intracranial aneurysms, cancer, x-rays, and computational fluid dynamics.** *AJNR Am J Neuroradiol* 2012;33: 991–92 CrossRef Medline
4. Cebral JR, Mut F, Raschi M, et al. **Analysis of hemodynamics and aneurysm occlusion after flow-diverting treatment in rabbit models.** *AJNR Am J Neuroradiol* 2014;35:1567–73 CrossRef Medline
5. Karmonik C, Yen C, Gabriel E, et al. **Quantification of speed-up and accuracy of multi-CPU computational flow dynamics simulations of hemodynamics in a posterior communicating artery aneurysm of complex geometry.** *J Neurointerv Surg* 2013;5(suppl 3):iii48–55 CrossRef Medline
6. Xiao L, Wang JY. **RNA-binding proteins and microRNAs in gastrointestinal epithelial homeostasis and diseases.** *Curr Opin Pharmacol* 2014;19:46–53 CrossRef Medline

7. Zhang J, Le TD, Liu L, et al. **Inferring condition-specific miRNA activity from matched miRNA and mRNA expression data.** *Bioinformatics* 2014;30:3070–77 [CrossRef Medline](#)
8. Wu CW, Cheng YW, Hsu NY, et al. **MiRNA-221 negatively regulated downstream p27Kip1 gene expression involvement in pterygium pathogenesis.** *Mol Vis* 2014;20:1048–56 [Medline](#)
9. Naito Y, Yasuno K, Tagawa H, et al. **MicroRNA-145 is a potential prognostic factor of scirrhous type gastric cancer.** *Oncol Rep* 2014;32:1720–26 [CrossRef Medline](#)
10. Peng SC, Liao CT, Peng CH, et al. **MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma.** *PLoS One* 2014;9:e102403 [CrossRef Medline](#)
11. Boele J, Persson H, Shin JW, et al. **PAPD5-mediated 3' adenylation and subsequent degradation of miR-21 is disrupted in proliferative disease.** *Proc Natl Acad Sci U S A* 2014;111:11467–72 [CrossRef Medline](#)
12. Li KK, Xia T, Ma FM, et al. **miR-106b is overexpressed in medulloblastomas and interacts directly with PTEN.** *Neuropathol Appl Neurobiol* 2015;41:145–64 [CrossRef Medline](#)
13. Jin H, Li C, Ge H, et al. **Circulating microRNA: a novel potential biomarker for early diagnosis of intracranial aneurysm rupture a case control study.** *J Transl Med* 2013;11:296 [CrossRef Medline](#)
14. Jiang Y, Zhang M, He H, et al. **MicroRNA/mRNA profiling and regulatory network of intracranial aneurysm.** *BMC Med Genomics* 2013;6:36 [CrossRef Medline](#)
15. Lee HJ, Yi JS, Lee HJ, et al. **Dysregulated expression profiles of MicroRNAs of experimentally induced cerebral aneurysms in rats.** *J Korean Neurosurg Soc* 2013;53:72–76 [CrossRef Medline](#)
16. Li L, Sima X, Bai P, et al. **Interactions of miR-34b/c and TP53 polymorphisms on the risk of intracranial aneurysm.** *Clin Dev Immunol* 2012;2012:567586 [CrossRef Medline](#)
17. Leeper NJ, Raiesdana A, Kojima Y, et al. **MicroRNA-26a is a novel regulator of vascular smooth muscle cell function.** *J Cell Physiol* 2011;226:1035–43 [CrossRef Medline](#)
18. Kadirvel R, Ding YH, Dai D, et al. **Differential gene expression in well-healed and poorly healed experimental aneurysms after coil treatment.** *Radiology* 2010;257:418–26 [CrossRef Medline](#)
19. Dai D, Ding YH, Danielson MA, et al. **Endovascular treatment of experimental aneurysms with use of fibroblast transfected with replication-deficient adenovirus containing bone morphogenetic protein-13 gene.** *AJNR Am J Neuroradiol* 2008;29:739–44 [CrossRef Medline](#)
20. Ding YH, Dai D, Lewis DA, et al. **Angiographic and histologic analysis of experimental aneurysms embolized with platinum coils, Matrix, and HydroCoil.** *AJNR Am J Neuroradiol* 2005;26:1757–63 [Medline](#)
21. Dai D, Yong-Hong D, Rezek I, et al. **Healing of saccular aneurysms following platinum coil embolization: lack of improved efficacy with vitamin C supplementation.** *J Neurointerv Surg* 2013;5:591–96 [CrossRef Medline](#)
22. Ding YH, Lewis DA, Kadirvel R, et al. **The Woven EndoBridge: a new aneurysm occlusion device.** *AJNR Am J Neuroradiol* 2011;32:607–11 [CrossRef Medline](#)
23. Mangrum WI, Farassati F, Kadirvel R, et al. **mRNA expression in rabbit experimental aneurysms: a study using gene chip microarrays.** *AJNR Am J Neuroradiol* 2007;28:864–69 [Medline](#)
24. Kadirvel R, Ding YH, Dai D, et al. **Gene expression profiling of experimental saccular aneurysms using deoxyribonucleic acid microarrays.** *AJNR Am J Neuroradiol* 2008;29:1566–69 [CrossRef Medline](#)
25. Kadirvel R, Ding YH, Dai D, et al. **Gene expression changes: five years after creation of elastase-induced aneurysms.** *J Vasc Interv Radiol* 2011;22:1447–51.e2 [CrossRef Medline](#)
26. Ozsolak F, Milos PM. **RNA sequencing: advances, challenges and opportunities.** *Nat Rev Genet* 2011;12:87–98 [CrossRef Medline](#)
27. Altes TA, Cloft HJ, Short JG, et al. **1999 ARRS Executive Council Award. Creation of saccular aneurysms in the rabbit: a model suitable for testing endovascular devices.** *American Roentgen Ray Society. AJR Am J Roentgenol* 2000;174:349–54 [CrossRef Medline](#)
28. Schroeder A, Mueller O, Stocker S, et al. **The RIN: an RNA integrity number for assigning integrity values to RNA measurements.** *BMC Mol Biol* 2006;7:3 [CrossRef Medline](#)
29. Lanzino G, Wakhloo AK, Fessler RD, et al. **Efficacy and current limitations of intravascular stents for intracranial internal carotid, vertebral, and basilar artery aneurysms.** *J Neurosurg* 1999;91:538–46 [CrossRef Medline](#)
30. Wang L, Wang S, Li W. **RSeQC: quality control of RNA-seq experiments.** *Bioinformatics* 2012;28:2184–85 [CrossRef Medline](#)
31. Trapnell C, Pachter L, Salzberg SL. **TopHat: discovering splice junctions with RNA-Seq.** *Bioinformatics* 2009;25:1105–11 [CrossRef Medline](#)
32. Langmead B, Trapnell C, Pop M, et al. **Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.** *Genome Biol* 2009;10:R25 [CrossRef Medline](#)
33. Anders S, Pyl TP, Huber W. **HTSeq—a Python framework to work with high-throughput sequencing data.** *Bioinformatics* 2015;31:166–69 [CrossRef Medline](#)
34. Robinson MD, McCarthy DJ, Smyth GK. **edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.** *Bioinformatics* 2010;26:139–40 [CrossRef Medline](#)
35. Khoo AA, Ogrizek-Tomas M, Bulovic A, et al. **ExoLocator—an online view into genetic makeup of vertebrate proteins.** *Nucleic Acids Res* 2014;42:D879–81 [CrossRef Medline](#)
36. Piotin M, Blanc R, Spelle L, et al. **Stent-assisted coiling of intracranial aneurysms: clinical and angiographic results in 216 consecutive aneurysms.** *Stroke* 2010;41:110–15 [CrossRef Medline](#)
37. Benjamini Y, Hochberg Y. **Controlling the false discovery rate—a practical and powerful approach to multiple testing.** *J Roy Stat Soc B Met* 1995;57:289–300
38. Krischek B, Kasuya H, Tajima A, et al. **Network-based gene expression analysis of intracranial aneurysm tissue reveals role of antigen presenting cells.** *Neuroscience* 2008;154:1398–407 [CrossRef Medline](#)
39. Peters DG, Kassam AB, Feingold E, et al. **Molecular anatomy of an intracranial aneurysm: coordinated expression of genes involved in wound healing and tissue remodeling.** *Stroke* 2001;32:1036–42 [CrossRef Medline](#)
40. Chalouhi N, Ali MS, Jabbour PM, et al. **Biology of intracranial aneurysms: role of inflammation.** *J Cereb Blood Flow Metab* 2012;32:1659–76 [CrossRef Medline](#)
41. Tulamo R, Frösen J, Junnikkala S, et al. **Complement system becomes activated by the classical pathway in intracranial aneurysm walls.** *Lab Invest* 2010;90:168–79 [CrossRef Medline](#)
42. Shi C, Awad IA, Jafari N, et al. **Genomics of human intracranial aneurysm wall.** *Stroke* 2009;40:1252–61 [CrossRef Medline](#)
43. Pera J, Korostynski M, Krzyszkowski T, et al. **Gene expression profiles in human ruptured and unruptured intracranial aneurysms: what is the role of inflammation?** *Stroke* 2010;41:224–31 [CrossRef Medline](#)
44. Leone V, D'Angelo D, Rubio I, et al. **MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1α.** *J Clin Endocrinol Metab* 2011;96:E1388–98 [CrossRef Medline](#)
45. Kadirvel R, Ding YH, Dai D, et al. **The influence of hemodynamic forces on biomarkers in the walls of elastase-induced aneurysms in rabbits.** *Neuroradiology* 2007;49:1041–53 [CrossRef Medline](#)
46. Samaras SE, Shi Y, Davidson JM. **CARP: fishing for novel mechanisms of neovascularization.** *J Invest Dermatol Symp Proc* 2006;11:124–31 [CrossRef Medline](#)
47. Samaras SE, Chen B, Koch SR, et al. **26S proteasome regulation of Ankrd1/CARP in adult rat ventricular myocytes and human microvascular endothelial cells.** *Biochem Biophys Res Commun* 2012;425:830–35 [CrossRef Medline](#)
48. Almodóvar-García K, Kwon M, Samaras SE, et al. **ANKRD1 acts as a transcriptional repressor of MMP13 via the AP-1 site.** *Mol Cell Biol* 2014;34:1500–11 [CrossRef Medline](#)
49. Mou L, Kang Y, Zhou Y, et al. **Neurokinin-1 receptor directly mediates glioma cell migration by up-regulation of matrix metalloproteinase-2 (MMP-2) and membrane type 1-matrix metalloproteinase (MT1-MMP).** *J Biol Chem* 2013;288:306–18 [CrossRef Medline](#)